Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Flucloxacillin 250mg powder for solution for injection vials
0501012G0AAACAC
|
Flucloxacillin sodium | Flucloxacillin sodium | Infections | 2 |
|
Flucloxacillin 500mg powder for solution for injection vials
0501012G0AAADAD
|
Flucloxacillin sodium | Flucloxacillin sodium | Infections | 2 |
|
Fortum 3g powder for solution for injection vials
0501021H0BBAGAH
|
Fortum | Ceftazidime pentahydrate | Infections | 2 |
|
Griseofulvin 150mg/5ml oral suspension
0502050B0AAAPAP
|
Griseofulvin (Systemic) | Griseofulvin | Infections | 2 |
|
Harvoni 90mg/400mg tablets
0503032F0BBAAAA
|
Harvoni | Ledipasvir/sofosbuvir | Infections | 2 |
|
Kivexa 600mg/300mg tablets
0503010Z0BBAAAA
|
Kivexa | Abacavir and lamivudine | Infections | 2 |
|
Lariam 250mg tablets
0504010L0BBAAAA
|
Lariam | Mefloquine hydrochloride | Infections | 2 |
|
Letermovir 240mg tablets
0503022F0AAAAAA
|
Letermovir | Letermovir | Infections | 2 |
|
Nebcin 80mg/2ml solution for injection vials
0501040U0BBACAC
|
Nebcin | Tobramycin | Infections | 2 |
|
Nevirapine 400mg modified-release tablets
0503010B0AAAEAE
|
Nevirapine | Nevirapine | Infections | 2 |
|
Pyrazinamide 500mg/5ml oral liquid
0501090N0AABBBB
|
Pyrazinamide | Pyrazinamide | Infections | 2 |
|
Ranovir 400mg tablets
0503021C0BEABAC
|
Ranovir | Aciclovir | Infections | 2 |
|
Rifampicin 150mg / Isoniazid 100mg tablets
0501090S0AAAAAA
|
Rifampicin/isoniazid | Rifampicin combined preparations | Infections | 2 |
|
Rifaximin 100mg/5ml oral suspension
0501070X0AAACAC
|
Rifaximin | Rifaximin | Infections | 2 |
|
Rocephin 2g powder for solution for injection vials
0501021G0BBACAD
|
Rocephin | Ceftriaxone sodium | Infections | 2 |
|
Symtuza 800mg/150mg/200mg/10mg tablets
050301000BBAGA0
|
Proprietary compound preparation BNF 0503010 | Other HIV infection preparations | Infections | 2 |
|
Teicoplanin 400mg powder for solution for injection vials
0501070T0AAACAC
|
Teicoplanin (Systemic) | Teicoplanin | Infections | 2 |
|
Tigecycline 50mg powder for solution for infusion vials
0501030Y0AAAAAA
|
Tigecycline | Tigecycline | Infections | 2 |
|
Tobi Podhaler 28mg inhalation powder capsules with device
0501040U0BCABAL
|
Tobi | Tobramycin | Infections | 2 |
|
Tobramycin 40mg/5ml oral solution
0501040U0AAAHAH
|
Tobramycin (Systemic) | Tobramycin | Infections | 2 |
|
Trimogal 200mg tablets
0501080W0BHABAE
|
Trimogal | Trimethoprim | Infections | 2 |
|
Tymbrineb 300mg/5ml nebuliser solution 5ml ampoules
0501040U0BFAAAG
|
Tymbrineb | Tobramycin | Infections | 2 |
|
Zinnat 125mg tablets
0501021K0BBAAAA
|
Zinnat | Cefuroxime axetil | Infections | 2 |
|
Zinnat 125mg/5ml oral suspension
0501021K0BBACAC
|
Zinnat | Cefuroxime axetil | Infections | 2 |
|
Abacavir 300mg tablets
0503010E0AAAAAA
|
Abacavir | Abacavir | Infections | 1 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.